. The importance of accelerated repopulation of residual tumour cells in rectal cancer has been inferred from the short interval over which relapse occurs in patients treated with surgical resection alone (Rich et al., 1993) . A measurement of a tumour's pretreatment growth potential might help assess an individual's risk of pelvic relapse and whether combinedmodality therapy would be ultimately successful in achieving local control, based on sterilisation of the primary tumour.
The curative treatment of rectal cancer presently consists in surgical resection of the primary disease, often together with pre-or post-operative pelvic radiotherapy, mostly combined with chemotherapy. Adjuvant preoperative radiotherapy has been shown to improve local control (Gerard et al., 1988) ; chemotherapy combined with post-operative radiotherapy improves disease-free and overall survival (Gastrointestinal Tumor Study Group, 1985; Krook et al., 1991) . Pathological staging of the resected tumour has been shown to be the single most important predictor of recurrence (Rich et al., 1983) . This knowledge, however, tells us little regarding the mechanism of treatment failure. Better predictors of whether the primary tumour will respond to radiotherapy and whether additional or modified treatment is required would be helpful. There is currently considerable interest in the use of pretreatment measurements of tumour dynamic kinetic parameters, for example tumour potential doubling time (Tpo), as predictive assays for treatment response to radiotherapy (e.g. Begg et al., 1992; Terry and Peters, 1993) . Furthermore, it is suggested that Tpo, may have value in selecting patients who would benefit from accelerated radiotherapy (Begg et al., 1992) or combined modality therapy (Rich et al., 1993) . The importance of accelerated repopulation of residual tumour cells in rectal cancer has been inferred from the short interval over which relapse occurs in patients treated with surgical resection alone (Rich et al., 1993) . A measurement of a tumour's pretreatment growth potential might help assess an individual's risk of pelvic relapse and whether combinedmodality therapy would be ultimately successful in achieving local control, based on sterilisation of the primary tumour.
The principal purpose of the present study was to determine the distributions of kinetic parameters for rectal cancer. The only comparable studies performed to date (Rew et al., 1991; Wilson et al., 1993a,b) included tumours from both colonic and rectal sites. Measurements were made of the kinetic parameters Tp, labelling index (LI) and the duration of S-phase (Ts). Tumour DNA ploidy and S-phase fractions (SPFs) were measured concurrently. Many studies have been performed to assess the predictive values of DNA ploidy and SPF of rectal tumours measured by DNA flow cytometry (Scott et al., 1987) and reviewed by Bauer (1993) . While measurements of these parameters may have prognostic value, tumour ploidy per se does not suggest logical and specific treatment modifications based on an acceptable model for tumour response. In contrast, kinetic measurements could be used to suggest a need for accelerated treatments or for cell cycle-specific drugs. The patients analysed in this study are being followed to determine treatment outcome, and any correlations with these measured parameters will be reported elsewhere. The DNA denaturation and nuclei staining procedures were the same for all samples and have been described in detail elsewhere for cultured cells and murine tumours (Carlton et al., 1991 
Materials and methods

Patient population
G2A
All cases had less than 20% debris; most had less than 10% debris.
Calculation of kinetic parameters Our analytical methodology is described in detail elsewhere (Terry et al., 1992a,b) (White et al., 1990) . The relative movement of the BrdUrdlabelled cells that remained undivided at the time of biopsy between the GI and G2M tumour peaks (measured from the univariate DNA histogram) was' used, together with v, to compute the duration of S-phase, Ts (Terry et al., 1992a,b Figure 2 . The mean LI of the aneuploid cells in the aneuploid tumours was 22% (Tables I and II) . Although this appears to be significantly higher than that observed in diplo -a Rectal cancer kinetics NHA Terry et al loid tumours, it is not legitimate to compare the two. In diploid tumours we cannot distinguish between normal and tumour cells and hence the overall LI reflects an average of the two populations. In order to estimate LI for the normal cell populations-in rectal tissue, we measured the LI of normal tissue taken from surgical resections from five patients. The mean LI was 1.3% (range 0.5-2.3%), a much lower value than that observed in tumours. Only 2 of 27 diploid tumours had LIs of less than 2.3%, indicating that the biopsies do indeed contain more proliferative tumour tissue. However, it should be noted that the LI of samples from normal tissue obtained by biopsy might be expected to be higher than those obtained by surgery since the biopsies would be enriched for proliferating epithelial cells in the mucosa, while the surgically removed tissue may contain more of the non-proliferating submucosal and muscularis cells.
The aneuploid (excluding recurrent) tumours appeared to show a trend towards decreasing LI with increasing stage (Table I ). This trend, however, was not statistically significant. The method of obtaining the sample had no significant effect on the measured values of LI.
The volumes of the tumours from 62 of the patients were measured from available computerised tomographic (CT) scans. Volumes ranged from 2.7 to 365 cm3. More advanced tumours tended to be larger than the earlier stage ones (r = 0.30, P = 0.017, Spearman's rank correlation); there was, however, extensive overlap between the different stages. For example the median (and quartile) values were 26.5 (8.9-53.5), 30.3 (16.3-42.4 ) and 55.6 (24.0-97.0) cm3 for T2, T3 and T4 tumours respectively. There was no correlation between volume and LI either when all stages were grouped or for samples within any of the individual stages (T2, T3 or T4; data not shown).
Both LI and SPF are approximate measures of a population's proliferative capability. Because of our interest in obtaining Tpot we need to label with BrdUrd and measure LI (or the related quantity v). We also calculated SPF values from the univariate DNA histograms without knowledge of the bivariate data and then compared the values of SPF and LI in this group of tumours. The values of SPF and LI for the total population were indeed related to each other as expected. The Spearman (non-parametric) correlation coefficient between the two was 0.76, which was highly significant at P<0.001. This correlation coefficient of 0.76 is, however, far from perfect, as can be seen from the scatter in the plot of the two values against each other (Figure 3) . The correlation between SPF and LI was much better for the diploid (r = 0.88) than for the aneuploid tumours (r = 0.62). Hence, despite the relationship between the parameters overall, the two measures may give very different values for any individual patient. The regression line relating the two parameters was SPF = (0.812 x LI) + 5.4% (all tumours). Thus, at low values, the SPF gives a higher value of proliferative index than does LI, probably because of the presence of noise, debris, normal cells and aggregates in the DNA histogram, despite the gating and debris subtraction procedures used. The regression equation for the diploid tumours, [SPF = (0.825 x LI) + 1.9%], had a much lower intercept than that for the aneuploid tumours.
Tumour ploidy Of the 101 evaluable tumours, 28 were diploid, and the rest were broadly, and bimodally, distributed with modes at DNA indices of about 1.2 and 1.6 (Figure 4) . Six of the tumours displayed two aneuploid subpopulations; the DNA index of the majority population was considered to be the DNA index of the tumour.
In the present study, based on results from aneuploid tumours, in which normal and tumour cells can be resolved, we found that a median of 48% (range 10-95%; quartiles 38-65%) of the cells in the suspensions prepared for flow cytometry were aneuploid and hence definitively tumour cells.
We analysed the dependence of the distribution of ploidies on the method used to obtain the sample (Table III) (Bauer, 1993) , but most of these studies included both colonic and rectal cancers. In a study in which rectal cancers predominated Giaretti and Santi (1990) reported a 75% incidence of aneuploidy that was independent of tumour grade but had some correlation with tumour size. In the present study there was a dependence of aneuploidy on stage (Table III) The important role of sample preparation in studies such as these can best be seen in the significant decrease in the incidence of aneuploid tumours when the data were obtained from biopsies as compared with surgical specimens (Table   III) . The possibility that it was due to missing the tumour site could not be confirmed when sigmoidoscopic biopsies were compared with material taken during endoscopic ultrasound examination. It is more likely that this reduced incidence of aneuploidy is related to the difficulty of making more than one preparation from small tumour biopsies. We have previously shown for head and neck cancer specimens that different pepsin digestion times can result in strikingly different flow cytometric profiles despite the fact that they may have been prepared from a homogenate of the same specimen (Terry and Peters, 1993) . Tumours that under optimal digestion conditions would show the presence of an aneuploid population might, if prepared inadequately, be misclassified as diploid. In the surgical specimens contributing to this study two (or more) different pepsin digestion times were routinely employed from a homogenate of the tissue sample. Since no pepsin digestion procedure can be considered 'standard', even for tumours of similar histologies from the same site, we suggest that the lowered incidence of aneuploid tumours observed in biopsies is due to the reduced possibility of making multiple preparations from very small (<25 mg) samples.
The measurement of SPF, or the fraction of cells both in S and G2M phases, by modelled deconvolution of DNA flow cytometric histograms has long been used as a surrogate measure of proliferative capacity. As recently reviewed (Bauer, 1993; Bauer et al., 1993) , the prognostic significance of SPF measurements in rectal cancer is unclear. Part of this difficulty has to do with the imprecisions involved in computing SPF from the histogram (Vindel0v and Christensen, 1990) owing to the presence of overlapping populations, presence of debris (Haag et al., 1987) , nature of the underlying algorithm that is employed to model the data (Dean, 1985; Scott et al., 1992) and type of fluorochrome employed (Dean et al., 1982) . Furthermore, there is well-documented evidence (Darzynkiewicz et al., 1980; Allison et al., 1983 Allison et al., , 1985 White et al., 1994) for the presence of non-cycling cells with S-phase DNA contents that will further confound the relationship between SPF (even if measured perfectly) and proliferative status. Despite these problems, some studies have indeed shown relationships between proliferative activity, as measured by SPF, and tumour response or treatment outcome (Crissman et al., 1989; Bauer, 1993; Bauer et al., 1993) .
Many of these difficulties in estimating proliferative activity can be obviated by measuring the fractions of DNAsynthesising cells with an independent marker (FITC-conjugated antibodies to incorporated BrdUrd). The data in Figure 3 show that, although there was a correlation between SPF and LI in the present study, there was considerable scatter in the data. For any given value of LI, values of SPF varied with a coefficient of variation of about 40%. The best fit regression did not pass through the origin but was offset to a positive value for SPF at a zero value of LI. This was probably due to the overestimation of SPF in samples with a low proliferative fraction, in which case the confounding problems detailed above would be most influential. Hence, it is likely that a measure of LI will be of more utility for estimating the proliferative capacity of cells within human tumours than is measurement of SPF (Vindel0v and Christensen, 1990 (1992) , in which no difference was observed between the range of LI values found for both diploid and aneuploid tumours. In aneuploid tumours we found that a median of 48% of the cells in the suspensions prepared for flow cytometry were aneuploid, and hence definitely tumour cells. We would expect the same percentages of normal and tumour cells in diploid tumours. For instance if 48% of the cells in tumours were tumour cells, the LI of these tumour cells is 21.7% and the LI of normal tissue is 1.3%, we would expect the LI of diploid tumours to be 11.1%. This is very close to the mean value of 12.0% we obtained. Therefore, we can attribute the lower LI of the diploid tumours to the admixture of normal and tumour cells. Rew et al. (1991) came to the same conclusion based on the total LI of aneuploid vs. diploid tumours. Among the aneuploid (excluding recurrent) tumours there was a non-significant trend for decreasing LI with increasing stage. There was also a trend for the later stage tumours to be larger than the earlier stages. The smaller tumours tended to have higher LI values, but this trend also did not reach significance. Costa et al. (1992) al., 1993) .
The wide range of values of LI (2% to > 50%) strengthens the potential for in vivo measurement of LI to be a useful candidate as a predictor of treatment response. There is a striking numerical difference between the LI values reported here and the only other similar study published to date (Rew et al., 1991) , where the authors report, for aneuploid tumours, a range of LI values of 2-26% with a much lower mean value of 12.1% (median 12.0%). [In a study of the reliability and reproducibility of measurement of kinetic parameters in colorectal cancer (Wilson et al., 1993a ) the same group reports mean values of LI of 14% and 16% depending on where the analysis was performed.] Differences in tumour sites appear to be the major contributor to the interlaboratory differences in LI. The inclusion of colonic and caecal cancers, with lower proliferative fractions, in the data of Rew et al. (1991) and Wilson et al. (1993a) , would reduce the mean value of the population. Several methodological differences can also contribute to the difference. Firstly, in the present study LI was calculated in terms of v and takes into account the division of both labelled and unlabelled cells in the time interval between BrdUrd administration and tumour sampling. The other authors correct only for the labelled cells that have divided, which would usually result in a slightly low estimate of the true value of LI. Modelling of the DNA profile to obtain the total number of tumour cells, as used in the present study, will result in lower numbers of cells in the total population than if the total is estimated directly from the bivariate DNA vs. BrdUrd histogram and also a higher LI. Furthermore, the present study also used objective criteria (White and Terry, 1992) to distinguish BrdUrd-labelled from unlabelled cells in instances when this distinction was not absolute.
The major advantage of the present methodology is that it allows for estimation of the 'dynamic' kinetic parameters of duration of S-phase, Ts, and the potential doubling time, Tpot As shown in Figure 5, (Wilson et al., 1993a,b; suggest that these parameters could be of value both as predictive assays of treatment outcome and for patient selection for altered treatment regimens. Furthermore, DNA diploid and aneuploid tumours must be evaluated separately, and the uncertainties in estimates of LI, Ts, and T.., in diploid tumours should be appreciated.
